Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin

• Published in: Revista iberoamericana de micología 2008-06, Vol.25 (2), p.92-100
• Main Authors: Gonzalez, M C, Gonzalez, JCM
• Format: Article
• Language: Spanish
• Subjects: Antifungal Agents - pharmacology; Antifungal Agents - therapeutic use; Aspergillus; Candida; Echinocandins - pharmacology; Echinocandins - therapeutic use; Humans; Mycoses - drug therapy
• ISSN: 1130-1406
• DOI: 10.1016/S1130-1406(08)70026-3

Anidulafungin is a new echinocandin antifungal agent which inhibits beta-1,3-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against Candida spp. and Aspergillus spp., including amphotericin B and triazole resistant strains. Due to the limited oral availability, anidulafungin in clinical use is available for parenteral administration only. Elimination of anidulafungin takes place via slow non-enzymatic degradation to inactive metabolites. Less than 10% and 1% of the initially administered drug is excreted unchanged into feces and urine, respectively. It does not require dosage adjustment in subjects with hepatic or renal impairment established. Anidulafungin is generally well tolerated. Adverse events appear not to be dose or infusion related. The most common treatment related adverse events are phlebitis, headache, nausea, vomiting and pyrexia. The lack of interactions with tacrolimus, cyclosporine and corticosteroids and its limited toxicity profile places anidulafungin as an attractive new option for the treatment of invasive fungal infections especially in transplant patients.